Sugi Predict

Sugi Predict / Compounds / SCHEMBL340106

SCHEMBL340106

SCHEMBL340106

CCOC(=O)c1cccc(OCc2ccccc2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 3/20 0.69
▸ NR4A2 P43354 5/20 0.68
▸ SMPD1 P17405 1/20 0.62
▸ SRD5A2 P31213 1/20 0.60
▸ PTPN1 P18031 1/20 0.59
▸ MEN1 O00255 3/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ HSP90AA1 P07900 1/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ CYP4F2 P78329 1/20 0.55
▸ CYP4A11 Q02928 1/20 0.55
▸ TP53 P04637 1/20 0.55
▸ PKM P14618 1/20 0.55
▸ NFKB1 P19838 1/20 0.55
▸ NFKB2 Q00653 1/20 0.55
▸ RELA Q04206 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3911336 0.92 MRGPRX4 (0.62) MAOBNR4A2SMPD1SRD5A2MEN1
SCHEMBL20830738 0.90 NR4A2 (0.74) MAOBNR4A2SMPD1SRD5A2PTPN1
SCHEMBL4400182 0.88 KMT2A (0.67) MAOBNR4A2MEN1KMT2AHSP90AA1
SCHEMBL9574667 0.88 NR4A2 (0.72) MAOBNR4A2SMPD1SRD5A2PTPN1
SCHEMBL9079254 0.87 MAPT (0.59) MAOBNR4A2SMN1; SMN2NPC1MAPT
SCHEMBL17978704 0.86 MAOB (0.66) MAOBNR4A2SMPD1SRD5A2PTPN1
SCHEMBL7433631 0.86 KMT2A (0.58) MAOBMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL7212709 0.86 NR4A2 (0.68) MAOBNR4A2SMPD1SRD5A2PTPN1
SCHEMBL19490437 0.85 L3MBTL1 (0.56) MAOBNR4A2SRD5A2MEN1KMT2A
SCHEMBL2771195 0.85 PPARG (0.57) NR4A2SMN1; SMN2NPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4578856-A1 HETEROCYCLIC COMPOUND Ubience Inc. (JP) 2025-07-02 — — EP disclosed
WO-2024071371-A1 HETEROCYCLIC COMPOUND ユビエンス株式会社 2024-04-04 — — WO disclosed
US-20170022180-A1 SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2017-01-26 — — US disclosed
EP-3112348-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES Tairx, Inc. (TW) 2017-01-04 — — EP disclosed
EP-2593435-B1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES TAIRX INC (TW) 2016-09-07 — — EP disclosed
US-20160229831-A1 SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2016-08-11 — — US disclosed
US-20160151369-A1 SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2016-06-02 — — US disclosed
EP-2970099-A1 SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS Acucela, Inc. (US) 2016-01-20 — — EP disclosed
CN-105209428-A Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders ACUCELA INC 2015-12-30 — — CN disclosed
CN-103347859-B Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives EFFICIENT PHARMA MANAGEMENT CORP. (CN) 2015-12-02 — — CN disclosed
US-7863314-B2 5-membered heterocycle-based p38 kinase inhibitors NOVARTIS AG (CH) 2011-01-04 — — US disclosed
US-7863314-B2 5-membered heterocycle-based p38 kinase inhibitors NOVARTIS AG (CH) 2011-01-04 — — US disclosed
EP-2231625-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-29 — — EP disclosed
US-7635779-B2 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-12-22 — — US disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 — — WO disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 — — WO disclosed
EP-1641764-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS Novartis AG (CH) 2006-04-05 — — EP disclosed
US-20050049288-A1 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS MEREO BIOPHARMA 1 LIMINTED (GB) 2005-03-03 — — US disclosed
WO-2005009973-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2005-02-03 — — WO disclosed
WO-2002022584-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049288-A1 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS MAPK1, MAP3K1, MAP3K8 MAOB 2961/4885NR4A2 1314/4885SMPD1 2577/4885
US-20160229831-A1 SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, PSEN2, CLN6 MAOB 90/4885NR4A2 1349/4885SMPD1 201/4885
US-20170022180-A1 SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, PSEN2, CLN6 MAOB 90/4885NR4A2 1349/4885SMPD1 201/4885
US-20160151369-A1 SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, PSEN2, CLN6 MAOB 90/4885NR4A2 1349/4885SMPD1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.